The GLP-1-agonist-GIPR-antagonist combination therapy reported in the present study was born from evidence of compromised gut-hormone function in obesity and diabetes as well as their postulated role in driving the beneficial metabolic effects following bariatric surgery. The gene discussed is GIPR; the disease is Obesity.